A STUDY WITH UPADACITINIB (ABT-494) IN SUBJECTS FROM CHINA AND SELECTED COUNTRIES WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS):